Safety and effectiveness of intravitreal bevacizumab and ranibizumab injections for treatment of retinal disease patients: an observational study

Conditions

retinal diseases or conditions that can be treated with bevacizumab or ranibizumab such as neovascular age&#45

Kumluang S, Ingsrisawang L, Sangroongruangsri S, Chaikledkaew U, Ratanapakorn T, Ruamviboonsuk P, Taweebanjongsin W, Choovuthayakorn J, Thoongsuwan S, Hanutsaha P, Kulvichit K, Ratanapojnard T, Wongsawad W, Leelahavarong P, Teerawattananon Y.

2019-03-2911 citations

10.1186/s12886-019-1086-1

Real-World Safety of Intravitreal Bevacizumab and Ranibizumab Treatments for Retinal Diseases in Thailand: A Prospective Observational Study.

Sangroongruangsri S, Chaikledkaew U, Kumluang S, Wu O, Geue C, Ratanapakorn T, Leelahavarong P, Ingsrisawang L, Ruamviboonsuk P, Taweebanjongsin W, Choovuthayakorn J, Singalavanija A, Hanutsaha P, Kulvichit K, Ratanapojnard T, Wongsawad W, Teerawattananon Y.

2018-09-0112 citations

10.1007/s40261-018-0678-5

Interventions

prior anti&#45

VEGF treated and anti&#45

VEGF&#45

naive patients who are going to receive intravitreal bevacizumab injection (IVB) during the study period ,prior anti&#45

naive patients who are going to receive intravitreal ranibizumab injection (IVR) during the study period

Treatment,Treatment

patients treated with intravitreal bevacizumab,patients treated with intravitreal ranibizumab

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: ï¿½ Sign informed consent which was approved by the institutional review board (IRB)/ independent ethics committees (IECs) of each hospital. ï¿½ age â‰¥ 18 years of either gender. ï¿½ be patients with retinal diseases who are treated or will be treated (previously untreated) with IVB or IVR before participating in this study. ï¿½ no contraindication to IVB or IVR such as allergy to the active ingredient or their excipients. ï¿½ no condition of infection around or at the eyes before receiving IVR. ï¿½ can participate in the study for at least 6 months after the enrollment.

Exclusion criteria

Exclusion criteria: ï¿½ have contraindication of bevacizumab or ranibizumab and their excipients ï¿½ switch between the investigational drugs within 6 months before the enrolment and during the 6-month of the study period Data collection of any subjects will be terminated when ï¿½ switch between the investigational drugs during the follow up period ï¿½ subjects want to withdraw from the study

Design outcomes

Primary

Measure	Time frame
nonfatal stroke withing one month after the intravitreal injection within 6 months case report form (data from medical records, patient-interview, and national databases),endophthalmitis withing one month after the intravitreal injection within 6 months case report form (data from medical records, patient-interview, and national databases)	—

Secondary

Measure	Time frame
change of best corrected visual acuity (BCVA) and CMT withing one month after the intravitreal injection within 6 months case report form (data from medical records, patient-interview, and national databases),arteriothrombotic and venous thrombotic events; upper GI bleeding; congestive heart failure withing one month after the intravitreal injection within 6 months case report form (data from medical records, patient-interview, and national databases)	—

Measure

Time frame

change of best corrected visual acuity (BCVA) and CMT withing one month after the intravitreal injection within 6 months case report form (data from medical records, patient-interview, and national databases),arteriothrombotic and venous thrombotic events; upper GI bleeding; congestive heart failure withing one month after the intravitreal injection within 6 months case report form (data from medical records, patient-interview, and national databases)

—

Countries

Thailand

Contacts

Public ContactSermsiri Sangroongruangsri

HITAP

sermsiri.s@hitap.net+66959599144

Outcome results

None listed